Bayer Korea said it has started marketing MEDRAD Centargo, a computed tomography (CT) injection medical device, which received approval from the Ministry of Food and Drug Safety in January.

Centargo is the first CT injection system introduced after Bayer announced its entry into the medical device market by launching its "Go-Direct” project. It aims to make Bayer Korea an integrated solution provider that provides customized solutions beyond product supply by combining medical devices and digital solutions with the existing contrast medium business.

The company emphasized that the device is a MEDRAD product that has received recognition for its technological prowess for a long time for its high efficiency and safety.

It explained that Centargo could help medical staff focus on patient care by minimizing the preparation time for contrast medium injection through an automated process and easy installation of parts.

Centargo uses a piston method to inject a contrast agent. Since the piston method uses a motor, the maximum achievable flow rate is higher than that of the existing rolling pump method, and the flow rate is also stable, the company said.

According to the InnoVatE study, a preclinical trial, Centargo showed the highest iodine delivery rate when used with Ultravist, Bayer's contrast medium, and showed a higher angiography enhancement value for a longer period compared to other equipment.

Bayer Korea stressed that the device is efficient and safe.

According to the company, the device minimizes air detection and injection through eight air management systems to prevent embolism caused by air entering the patient's blood vessels. It prevents cross-contamination and microbial contamination through a double-check valve in the patient line.

"We are happy to provide innovative experiences to Korean medical staff, with Centargo, which is already available in Europe and APAC, has received recognition for its product quality, efficiency, and reliability, and as a sustainable product that reduces waste and waste of contrast agents," said Leona Mulcahy, head of Bayer Korea’s Radiology Division.

She added that Bayer aims to become an integrated solution provider and a leader in Korea's radiology field that helps medical professionals make complex decisions through contrast agents, medical devices, and integrated software solutions.